Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Viralytics
Biotech
Merck ditches Cavatak more than 4 years after buying Viralytics
More than four years after handing over nearly $400 million to buy Viralytics, Merck is axing the sole therapy acquired in the deal.
Max Bayer
Oct 27, 2022 10:40am
New discoveries in cancer and hearing loss—News of Note
Jul 8, 2019 11:14am
Merck inks $394M takeover of oncolytic virus play Viralytics
Feb 21, 2018 5:39am
Viralytics' oncolytic virus aces checkpoint inhibitor combo trials
Nov 21, 2016 9:05am
